Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430531 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Sphenopalatine Ganglion Block for Post-Dural Puncture Headache
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03430531 is a Phase 2 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 6 participants.
The verdict
NCT03430531, a Phase 2 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The objective of the study is to determine the effectiveness of Spheno-Palatine (SP) ganglion block to alleviate the pain of post-dural puncture headache (PDPH).
Interventions
- DRUG Lidocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-05-31 |
| Est. Completion | 2022-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03430531
The ClinicalTrials.gov registry entry for NCT03430531 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lidocaine is the first listed.
NCT03430531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03430531 about?
NCT03430531 is a clinical study titled "Effectiveness of Sphenopalatine Ganglion Block for Post-Dural Puncture Headache". The objective of the study is to determine the effectiveness of Spheno-Palatine (SP) ganglion block to alleviate the pain of post-dural puncture headache (PDPH).
What is the current status of trial NCT03430531?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-05-31. Estimated completion is 2022-03-11.
What interventions are being tested in trial NCT03430531?
The interventions under investigation include: Lidocaine (DRUG).
Who is sponsoring clinical trial NCT03430531?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.